Journal of Breast Cancer

Korean Breast Cancer Society (한국유방암학회)
권호 표지
DOI QR코드

DOI QR Code

Neoadjuvant Chemotherapy and Prognosis of Pregnancy-Associated Breast Cancer: A Time-Trends Study of the Korean Breast Cancer Registry Database

  • Bae, Soo Youn (Department of Surgery, Korea University Anam Hospital, Korea University College of Medicine) ;
  • Kim, Ku Sang (Breast-Thyroid Center, Ulsan City Hospital) ;
  • Kim, Jeong-Soo (Department of Surgery, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Lee, Sae Byul (Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Park, Byeong-Woo (Department of Surgery, Yonsei University College of Medicine) ;
  • Lee, Seok Won (Department of Surgery, Pusan National University Hospital, Pusan National University School of Medicine) ;
  • Lee, Hyouk Jin (Breast-Thyroid Center, Saegyaero Hospital) ;
  • Kim, Hong Kyu (Department of Surgery, Korea University Anam Hospital, Korea University College of Medicine) ;
  • You, Ji-Young (Department of Surgery, Korea University Anam Hospital, Korea University College of Medicine) ;
  • Jung, Seung Pil (Department of Surgery, Korea University Anam Hospital, Korea University College of Medicine) ;
  • Korean Breast Cancer Society (Korean Breast Cancer Society)
  • Received : 2018.05.28
  • Accepted : 2018.11.15
  • Published : 2018.12.31
⟨ Previous Next ⟩

Abstract

Purpose: Pregnancy-associated breast cancer (PABC) is rare, and its cause and prognosis are not well known. Additionally, treatment is limited with respect to the risk to the fetus. The purpose of this study was to investigate the characteristics and treatment trends of PABC and the survival rate according to the treatment. Methods: In the Korean Breast Cancer Society Registry database, women younger than 50 years and who were diagnosed with breast cancer from 1996 to 2015 were included. PABC was defined as breast cancer diagnosed during pregnancy or within 1 year after delivery. Results: We examined 411 patients with PABC and 83,381 patients with non-PABC. Over time, the proportions of patients undergoing breast-conserving surgery and sentinel lymph node biopsy increased, and neoadjuvant chemotherapy and radiation therapy administration rates also increased. In the past, the overall survival of patients with PABC was poorer than that of patients with non-PABC, but there was no difference in overall survival rates in more recent years. There was no difference in overall survival rates between patients who received neoadjuvant chemotherapy (hazard ratio [HR], 1.28; 95% confidence interval [CI], 0.66-2.49; p=0.459), but PABC conferred poorer prognosis than non-PABC in patients receiving adjuvant chemotherapy (HR, 1.63; 95% CI, 1.27-2.08; p<0.001). Conclusion: There was no difference in the prognosis between patients with PABC and those with non-PABC receiving neoadjuvant chemotherapy. The increase in neoadjuvant chemotherapy according to current treatment guidelines is expected to improve the survival rate of patients with PABC.

Keywords

Acknowledgement

Supported by : National Research Foundation of Korea, Korea University

References

  1. Smith LH, Danielsen B, Allen ME, Cress R. Cancer associated with obstetric delivery: results of linkage with the California cancer registry. Am J Obstet Gynecol 2003;189:1128-35. https://doi.org/10.1067/S0002-9378(03)00537-4
  2. Parente JT, Amsel M, Lerner R, Chinea F. Breast cancer associated with pregnancy. Obstet Gynecol 1988;71(6 Pt 1):861-4.
  3. Lee YY, Roberts CL, Dobbins T, Stavrou E, Black K, Morris J, et al. Incidence and outcomes of pregnancy-associated cancer in Australia, 1994-2008: a population-based linkage study. BJOG 2012;119:1572-82. https://doi.org/10.1111/j.1471-0528.2012.03475.x
  4. Stensheim H, Moller B, van Dijk T, Fossa SD. Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. J Clin Oncol 2009;27:45-51. https://doi.org/10.1200/JCO.2008.17.4110
  5. Amant F, von Minckwitz G, Han SN, Bontenbal M, Ring AE, Giermek J, et al. Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol 2013;31:2532-9. https://doi.org/10.1200/JCO.2012.45.6335
  6. Litton JK, Warneke CL, Hahn KM, Palla SL, Kuerer HM, Perkins GH, et al. Case control study of women treated with chemotherapy for breast cancer during pregnancy as compared with nonpregnant patients with breast cancer. Oncologist 2013;18:369-76. https://doi.org/10.1634/theoncologist.2012-0340
  7. Hartman EK, Eslick GD. The prognosis of women diagnosed with breast cancer before, during and after pregnancy: a meta-analysis. Breast Cancer Res Treat 2016;160:347-60. https://doi.org/10.1007/s10549-016-3989-3
  8. Azim HA Jr, Peccatori FA, Brohee S, Branstetter D, Loi S, Viale G, et al. RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. Breast Cancer Res 2015;17:24. https://doi.org/10.1186/s13058-015-0538-7
  9. Azim HA Jr, Brohee S, Peccatori FA, Desmedt C, Loi S, Lambrechts D, et al. Biology of breast cancer during pregnancy using genomic profiling. Endocr Relat Cancer 2014;21:545-54. https://doi.org/10.1530/ERC-14-0111
  10. Kroman N, Mouridsen HT. Prognostic influence of pregnancy before, around, and after diagnosis of breast cancer. Breast 2003;12:516-21. https://doi.org/10.1016/S0960-9776(03)00159-0
  11. Woo JC, Yu T, Hurd TC. Breast cancer in pregnancy: a literature review. Arch Surg 2003;138:91-8. https://doi.org/10.1001/archsurg.138.1.91
  12. Paluch-Shimon S, Pagani O, Partridge AH, Abulkhair O, Cardoso MJ, Dent RA, et al. ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). Breast 2017;35:203-17. https://doi.org/10.1016/j.breast.2017.07.017
  13. Johansson AL, Andersson TM, Hsieh CC, Jirstrom K, Cnattingius S, Fredriksson I, et al. Tumor characteristics and prognosis in women with pregnancy-associated breast cancer. Int J Cancer 2018;142:1343-54. https://doi.org/10.1002/ijc.31174
  14. Eibye S, Kjær SK, Mellemkjær L. Incidence of pregnancy-associated cancer in Denmark, 1977-2006. Obstet Gynecol 2013;122:608-17. https://doi.org/10.1097/AOG.0b013e3182a057a2
  15. Loibl S, Schmidt A, Gentilini O, Kaufman B, Kuhl C, Denkert C, et al. Breast cancer diagnosed during pregnancy: adapting recent advances in breast cancer care for pregnant patients. JAMA Oncol 2015;1:1145-53. https://doi.org/10.1001/jamaoncol.2015.2413
  16. Min SY, Kim Z, Hur MH, Yoon CS, Park EH, Jung KW, et al. The basic facts of Korean breast cancer in 2013: results of a nationwide survey and breast cancer registry database. J Breast Cancer 2016;19:1-7. https://doi.org/10.4048/jbc.2016.19.1.1
  17. Ahn SH, Son BH, Kim SW, Kim SI, Jeong J, Ko SS, et al. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea: a report from the Korean Breast Cancer Society. J Clin Oncol 2007;25:2360-8. https://doi.org/10.1200/JCO.2006.10.3754
  18. Kim YG, Jeon YW, Ko BK, Sohn G, Kim EK, Moon BI, et al. Clinicopathologic characteristics of pregnancy-associated breast cancer: results of analysis of a nationwide breast cancer registry database. J Breast Cancer 2017;20:264-9. https://doi.org/10.4048/jbc.2017.20.3.264
  19. Raut CP, Daley MD, Hunt KK, Akins J, Ross MI, Singletary SE, et al. Anaphylactoid reactions to isosulfan blue dye during breast cancer lymphatic mapping in patients given preoperative prophylaxis. J Clin Oncol 2004;22:567-8. https://doi.org/10.1200/jco.2004.22.90140.567
  20. Gropper AB, Calvillo KZ, Dominici L, Troyan S, Rhei E, Economy KE, et al. Sentinel lymph node biopsy in pregnant women with breast cancer. Ann Surg Oncol 2014;21:2506-11. https://doi.org/10.1245/s10434-014-3718-2
  21. Pandit-Taskar N, Dauer LT, Montgomery L, St Germain J, Zanzonico PB, Divgi CR. Organ and fetal absorbed dose estimates from 99mTcsulfur colloid lymphoscintigraphy and sentinel node localization in breast cancer patients. J Nucl Med 2006;47:1202-8.
  22. Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol 2004;5:283-91. https://doi.org/10.1016/S1470-2045(04)01466-4
  23. Bines J, Earl H, Buzaid AC, Saad ED. Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer: does the sequence matter? Ann Oncol 2014;25:1079-85. https://doi.org/10.1093/annonc/mdu007
  24. Loibl S, Han SN, von Minckwitz G, Bontenbal M, Ring A, Giermek J, et al. Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol 2012;13:887-96. https://doi.org/10.1016/S1470-2045(12)70261-9
  25. National Toxicology Program. NTP monograph: developmental effects and pregnancy outcomes associated with cancer chemotherapy use during pregnancy. NTP Monogr 2013;(2):i-214.
  26. Lenhard MS, Bauerfeind I, Untch M. Breast cancer and pregnancy: challenges of chemotherapy. Crit Rev Oncol Hematol 2008;67:196-203. https://doi.org/10.1016/j.critrevonc.2008.02.007
  27. Molckovsky A, Madarnas Y. Breast cancer in pregnancy: a literature review. Breast Cancer Res Treat 2008;108:333-8. https://doi.org/10.1007/s10549-007-9616-6
  28. Genin AS, Lesieur B, Gligorov J, Antoine M, Selleret L, Rouzier R. Pregnancy-associated breast cancers: do they differ from other breast cancers in young women? Breast 2012;21:550-5. https://doi.org/10.1016/j.breast.2012.05.002
  29. Cruz GI, Martinez ME, Natarajan L, Wertheim BC, Gago-Dominguez M, Bondy M, et al. Hypothesized role of pregnancy hormones on HER2+ breast tumor development. Breast Cancer Res Treat 2013;137:237-46. https://doi.org/10.1007/s10549-012-2313-0
  30. Zagouri F, Sergentanis TN, Chrysikos D, Papadimitriou CA, Dimopoulos MA, Bartsch R. Trastuzumab administration during pregnancy: a systematic review and meta-analysis. Breast Cancer Res Treat 2013;137:349-57. https://doi.org/10.1007/s10549-012-2368-y